Management of treatment resistance in schizophrenia

Biological Psychiatry

Volumn 50, Issue 11, 2001, Pages 898-911

  Conley, Robert R ^a,b,c   Kelly, Deanna L ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotic; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERANCE; EVALUATION; HOSPITALIZATION; HUMAN; NEUROBIOLOGY; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME; VIOLENCE;

ADRENERGIC BETA-ANTAGONISTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; LITHIUM; SCHIZOPHRENIA;

EID: 0035667156     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(01)01271-9     Document Type: Conference Paper

References (172)

1. Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'
2. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
3. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
4. Long-term reserpine use in selected refractory outpatients
5. Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment
6. Myoclonus in patients treated with clozapine: A case series
7. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
8. Pharmacological treatment strategies in the non-responsive schizophrenic patient
9. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
10. Clozapine in aggression
11. Neuroleptic-resistant schizophrenia treated with clozapine and ETC
12. Neuroleptic-resistant schizophrenia treated with clozapine and ETC
13. Neuroleptics and reserpine in refractory psychoses
14. Concurrent administration of clozapine and ECT: A successful therapeutic strategy for a patient with treatment-resistant schizophrenia
15. Cerebral morphometry and clozapine treatment in schizophrenia
16. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
17. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns
18. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia
19. Defining treatment refractoriness in schizophrenia
20. Successful outcome using quetiapine in a case of treatment-resistant schizophrenia with assaultive behavior
21. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome
22. Catching up on schizophrenia
23. Schizophrenia: Improving outcome
24. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients
25. Patient response and resource management: Another view of clozapine treatment of schizophrenia
26. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials
27. Maintenance ECT in treatment-resistant schizophrenia
28. Clozapine augmentation safety and efficacy
29. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
30. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis
31. When symptoms persist: Choosing among alternative somatic treatments for schizophrenia
32. Changes in the use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998
33. Lithium carbonate, haloperidol, and irreversible brain damage
34. Clinical action of remoxipride
35. Time to clozapine response in a standardized trial
36. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia
37. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response
38. Effect of risperidone on hostility in schizophrenia
39. Antipsychotic drugs: Clinical pharmacology and therapeutic use
40. Addition of risperidone to clozapine therapy in chronically psychotic inpatients
41. Lithium treatment in schizophrenia and schizoaffective disorders
42. Conventional antipsychotic medications for schizophrenia
43. Combined treatment of schizophrenic psychosis with haloperidol and valproate
44. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine
45. Clozapine plus lamotrigine in treatment-resistant schizophrenia
46. Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study
47. Prolonged recovery in first-episode psychosis
48. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of a demonstrated, partial response to conventional antipsychotic treatment
49. Mental disorders and homicidal behavior in Finland
50. Clozapine eligibility among state hospital patients
51. ICI 204,636, a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia
52. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: Relation to extrapyramidal side effects
53. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
54. Compliance with antipsychotic drug treatment: Influence of side effects
55. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia
56. The Expert Consensus Guidelines for treatment treating depression in bipolar disorder
57. A double-blind comparison of valproate and lithium in the treatment of acute mania
58. The combined use of neuroleptics and ECT in drug resistant schizophrenic patients
59. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine
60. Lithium in chronic schizophrenia
61. Olanzapine augmentation of clozapine
62. Very high reserpine dosage in the treatment of chronic schizophrenia
63. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazine-imipramine
64. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics
65. High potency neuroleptics and violence in schizophrenics
66. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia
67. Effects of stringent criteria on eligibility for clozapine among public mental health clients
68. Change in haloperidol level due to carbamazepine: A complicating factor in combined medication for schizophrenia
69. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia
70. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
71. Schizophrenia
72. Psychopharmacologic treatment of schizophrenia
73. Case report of a possible interaction between neuroleptics and carbamazepine
74. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders
75. Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service
76. Influence of neuroleptic dose and class in treatment-resistant schizophrenia relapse
77. Treatment of neuroleptic-resistant schizophrenic relapse
78. Interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: An unbiased cell-counting study
79. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia
80. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
81. Reconsideration of reserpine in the treatment of schizophrenia
82. Combined electoconvulsive-clozapine therapy
83. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics?
84. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report
85. Prediction of outcome in first-episode schizophrenia
86. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
87. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label prospective trial
88. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia
89. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: A double-blind clinical trial
90. A dose-outcome analysis of risperidone
91. Restraint, seclusion, and clozapine
92. Aggressive behaviors among the institutionalized elderly
93. Antipsychotic drugs and relapse prevention
94. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of North American trials
95. Risperidone in the treatment of schizophrenia
96. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study
97. Risperidone augmentation of clozapine
98. A selective review of recent North American long-term followup studies of schizophrenia
99. Defining treatment refractoriness in schizophrenia
100. New drugs for the treatment of schizophrenia
101. An overview of the mechanism of action of clozapine
102. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
103. The evolution of treatment-resistance: Biologic implications
104. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
105. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug
106. The TMAP schizophrenia algorithms
107. Risperidone and clozapine combination for the treatment of refractory schizophrenia
108. Lithium-neuroleptic neurotoxicity is dose dependent
109. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients
110. Treatment resistant chronic psychopathology and CT scans in schizophrenia
111. The brief psychiatric rating scale
112. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia
113. Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia
114. Plasma homovanillic acid as an index of central dopaminergic activity: Studies in schizophrenic patients
115. Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine
116. Non-lithium treatment for bipolar disorder
117. High dose chlorpromazine therapy in chronic schizophrenia: Report of national institute of mental health - Psychopharmacology research branch collaborative study group
118. Olanzapine and sulpiride: A preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia
119. Clozapine and risperidone: Combination/augmentation treatment of refractory schizophrenia: A preliminary observation
120. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital
121. Use of high-dose olanzapine in refractory psychosis
122. Clozapine: Current status and role in the pharmacotherapy of schizophrenia
123. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients
124. Seroquel in a resistant schizophrenic with negative and positive symptoms
125. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: I. Relapse rates after one year
126. Cost-effectiveness of clozapine in patients with high and low levels of hospital use
127. Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia: The department of veterans affairs cooperative study group on clozapine in refractory schizophrenia
128. How long to wait for a response to clozapine: A comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia
129. Benzodiazepines in chronic schizophrenia
130. Update on the clinical efficacy and side effects of clozapine
131. An open trial of olanzapine in patients with treatment-refractory psychoses
132. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia
133. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients
134. Poor neuroleptic response in acutely exacerbated schizophrenic patients
135. Clinical implications of clozapine discontinuation: Report of an NIMH workshop
136. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study
137. The use of carbamazepine in the treatment of schizophrenia and schizoaffective psychosis: A review
138. Efficacy of electroconvulsive therapy in schizophrenia, mania, and other disorders: I
139. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients
140. Standards of care and clinical algorithms for treating schizophrenia
141. Risperidone-reserpine combination in refractory psychosis
142. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
143. Predictors of response to neuroleptic treatment in schizophrenia
144. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine
145. Quetiapine for refractory schizophrenia
146. Clozapine in tardive dyskinesia: Observations from human and animal model studies
147. An open trial of risperidone augmentation of partial response to clozapine
148. Refractory schizophrenia and atypical antipsychotics
149. Estimating clozapine's cost to the nation
150. Electroconvulsive therapy for schizophrenia
151. Management of treatment-resistant schizophrenia with olanzapine
152. Review of recent clinical studies with olanzapine
153. Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?
154. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients
155. Clozapine effects on hostility and aggression in schizophrenia
156. Efficacy of beta-blocker supplementation for schizophrenia: A systematic review of randomized trials
157. Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
158. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia
159. Optimal dosing with risperidone: Updated recommendations
160. Clinical review of clozapine treatment in a state hospital
161. Risperidone in treatment-refractory schizophrenia
162. Dopamine blockade and clinical response: Evidence for two biological subgroups of schizophrenia
163. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia
164. Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia
165. A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder
166. Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia